SCHEMBL5353695

SCHEMBL5353695

[O]C(=O)c1occ2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.36
HSD17B10 Q99714 4/20 0.36
HPGD P15428 3/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 2/20 0.36
NR4A1 P22736 1/20 0.36
NR4A2 P43354 1/20 0.36
NR4A3 Q92570 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
WDR5 P61964 1/20 0.34
MAOB P27338 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
TDP1 Q9NUW8 3/20 0.33
TSHR P16473 2/20 0.33
CYP2A6 P11509 1/20 0.33
LDHA P00338 1/20 0.33
MMP3 P08254 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16292878 0.85 KDM4E (0.38) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL547449 0.83 KDM4E (0.45) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL649403 0.82 ALDH1A1 (0.41) KDM4EHSD17B10HPGDKMT2AALDH1A1
Hydrochloric Acid SCHEMBL11395268 0.82 LDHA (0.44) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL112635 0.82 MAPT (0.42) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL826674 0.82 KDM4E (0.35) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL5309791 0.82 CA12 (0.37) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL3383913 0.82 KDM4E (0.35) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL9565260 0.82 KDM4E (0.35) KDM4EHSD17B10HPGDKMT2AALDH1A1
SCHEMBL8620985 0.79 ALDH1A1 (0.41) KDM4EHSD17B10HPGDKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 KDM4E 855/4885HSD17B10 3089/4885HPGD 1479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.